Elkedonia

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Xylo

The company develops non-hallucinogenic neuroplastogens to treat psychiatric and neurological disorders in patients with unmet medical needs.

Delix

This company develops non-hallucinogenic neuroplasticity-promoting medicines to treat neuropsychiatric and neurodegenerative conditions for patients with brain disorders.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Pangea Botanica

This company develops medicines for neurological and mental health disorders using an artificial intelligence platform to discover neuroactive molecules from medicinal plants.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Brandaris

This biotechnology company develops neuropsychiatric drug candidates to treat patients with mental health disorders including depression and anxiety.